title: Photodynamic therapy with verteporfin in mallatia leventinese.
abstract: OBJECTIVE
  To describe a case of a patient with documented genetic mallatia leventinese who developed a classic choroidal neovascular membrane and underwent photodynamic therapy (PDT) with verteporfin (Visudyne; CIBA Vision Corp., Duluth, GA).
  
  
  METHODS
  Interventional case report.
  
  
  METHODS
  The patient underwent a complete ophthalmologic evaluation and fluorescein angiography. Photodynamic therapy with verteporfin was performed.
  
  
  METHODS
  Clinical and angiographic records were analyzed for evidence of changes in visual acuity, clinically evident subretinal fluid and the extent of fluorescein leakage from choroidal neovascularization (CNV).
  
  
  RESULTS
  Three weeks after treatment, a fluorescein angiogram showed closure of the neovascular membrane, no evident subretinal fluid was seen, and visual acuity had improved from 20/60- to 20/40. Nine weeks after the application, fluorescein angiography demonstrated a microscopic hyperfluorescent spot at the site of the previously active CNV at which a small area of shallow subretinal fluid was observed, and visual acuity was 20/50. Thirty-four weeks after PDT, visual acuity was 20/60, subretinal fluid resolved, and fluorescein angiography did not show any further changes.
  
  
  CONCLUSIONS
  Photodynamic therapy with verteporfin may be considered as a possible treatment in patients with mallatia leventinese who develop classic CNV.
authors.affiliation: LuEsther T. Mertz Retinal Research Center/Manhattan Eye, Ear & Throat Hospital, New York, New York, USA.
authors.forename: Marcos A
authors.initials: MA
authors.lastname: Dantas
authors.forename: Jason S
authors.initials: JS
authors.lastname: Slakter
authors.forename: Silvana
authors.initials: S
authors.lastname: Negrao
authors.forename: Roberto A
authors.initials: RA
authors.lastname: Fonseca
authors.forename: Tatsushi
authors.initials: T
authors.lastname: Kaga
authors.forename: Lawrence A
authors.initials: LA
authors.lastname: Yannuzzi
mesh_terms: D000328:Adult; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D015593:Retinal Drusen / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin